CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice

Diabetes

Volumn 64, Issue 4, 2015, Pages 1329-1340

  Citro, Antonio ^a,b   Valle, Andrea ^a   Cantarelli, Elisa ^a   Mercalli, Alessia ^a   Pellegrini, Silvia ^a   Liberati, Daniela ^a   Daffonchio, Luisa ^c   Kastsiuchenka, Olga ^c   Ruffini, Pier Adelchi ^c   Battaglia, Manuela ^a   Allegretti, Marcello ^c   Piemonti, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Chemistry Section   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; LADARIXIN; REPARIXIN; 2-(4-ISOBUTYLPHENYL)PROPIONYLMETHANESULFONAMIDE; SULFONAMIDE;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BONE MARROW; BONE MARROW CELL; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LEUKOCYTE; LYMPH NODE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PATHOGENESIS; PRIORITY JOURNAL; SPLEEN; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; NONOBESE DIABETIC MOUSE; PANCREAS ISLET;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ISLETS OF LANGERHANS; MICE; MICE, INBRED NOD; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SULFONAMIDES;

EID: 84929504696     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0443     Document Type: Article

References (54)

1. von Herrath M, Peakman M, Roep B. Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol 2013;172: 186-202
2. Campbell-Thompson ML, Atkinson MA, Butler AE, et al. The diagnosis of insulitis in human type 1 diabetes. Diabetologia 2013;56: 2541-2543
3. Coppieters KT, Dotta F, Amirian N, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012;209: 51-60
4. Nepom GT, Ehlers M, Mandrup-Poulsen T. Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol 2013;149: 279-285
5. Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG. Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother 2014;10: 838-846
6. Waldron-Lynch F, Herold KC. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov 2011;10: 439-452
7. Lernmark A, Larsson HE. Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 2013;9: 92-103
8. Mortier A, Van Damme J, Proost P. Overview of the mechanisms regulating chemokine activity and availability. Immunol Lett 2012;145: 2-9
9. Bonecchi R, Galliera E, Borroni EM, Corsi MM, Locati M, Mantovani A. Chemokines and chemokine receptors: An overview. Front Biosci (Landmark Ed) 2009;14: 540-551
10. Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol 2008;9: 949-952
11. Citro A, Cantarelli E, Piemonti L. Anti-inflammatory strategies to enhance islet engraftment and survival. Curr Diab Rep 2013;13: 733-744
12. Sarkar SA, Lee CE, Victorino F, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 2012;61: 436-446
13. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and betacell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5: 219-226
14. Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: Cellular origin, regulation and function. Trends Endocrinol Metab 2010;21: 261-267
15. Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 2003;63: 7451-7461
16. Kriegel MA, Rathinam C, Flavell RA. Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells. Proc Natl Acad Sci U S A 2012;109: 3457-3462
17. Melzi R, Mercalli A, Sordi V, et al. Role of CCL2/MCP-1 in islet transplantation. Cell Transplant 2010;19: 1031-1046
18. Martin AP, Rankin S, Pitchford S, Charo IF, Furtado GC, Lira SA. Increased expression of CCL2 in insulin-producing cells of transgenic mice promotes mobilization of myeloid cells from the bone marrow, marked insulitis, and diabetes. Diabetes 2008;57: 3025-3033
19. Rhode A, Pauza ME, Barral AM, et al. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 2005;175: 3516-3524
20. Roep BO, Kleijwegt FS, van Halteren AG, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010;159: 338-343
21. Citro A, Cantarelli E, Maffi P, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 2012;122: 3647-3651
22. Cowley MJ, Weinberg A, Zammit NW, et al. Human islets express a marked proinflammatory molecular signature prior to transplantation. Cell Transplant 2012;21: 2063-2078
23. Burke SJ, Lu D, Sparer TE, et al. NF-kB and STAT1 control CXCL1 and CXCL2 gene transcription. Am J Physiol Endocrinol Metab 2014;306: E131-E149
24. Takahashi K, Ohara M, Sasai T, et al. Serum CXCL1 concentrations are elevated in type 1 diabetes mellitus, possibly reflecting activity of anti-islet autoimmune activity. Diabetes Metab Res Rev 2011;27: 830-833
25. Van Sickle BJ, Simmons J, Hall R, Raines M, Ness K, Spagnoli A. Increased circulating IL-8 is associated with reduced IGF-1 and related to poor metabolic control in adolescents with type 1 diabetes mellitus. Cytokine 2009;48: 290-294
26. Hakimizadeh E, Shamsizadeh A, Nazari M, et al. Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: A study on Iranian diabetic patients. Clin Lab 2013; 59: 531-537
27. Diana J, Simoni Y, Furio L, et al. Crosstalk between neutrophils, B-1α cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 2013;19: 65-73
28. Harsunen MH, Puff R, D'Orlando O, et al. Reduced blood leukocyte and neutrophil numbers in the pathogenesis of type 1 diabetes. Horm Metab Res 2013;45: 467-470
29. Valle A, Giamporcaro GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes 2013;62: 2072-2077
30. Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004;101: 11791-11796
31. Bertini R, Barcelos LS, Beccari AR, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. Br J Pharmacol 2012;165: 436-454
32. Allegretti M, Cesta MC, Garin A, Proudfoot AE. Current status of chemokine receptor inhibitors in development. Immunol Lett 2012;145: 68-78
33. Pujol-Autonell I, Ampudia RM, Monge P, et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol 2013;2013: 346987
34. De Paola M, Buanne P, Biordi L, Bertini R, Ghezzi P, Mennini T. Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures. Neuroimmunomodulation 2007;14: 310-316
35. Garau A, Bertini R, Mosca M, et al. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat. Eur Cytokine Netw 2006;17: 35-41
36. Diana J, Lehuen A. Macrophages and β-cells are responsible for CXCR2-mediated neutrophil infiltration of the pancreas during autoimmune diabetes. EMBO Mol Med 2014;6: 1090-1104
37. Martin AP, Grisotto MG, Canasto-Chibuque C, et al. Islet expression of M3 uncovers a key role for chemokines in the development and recruitment of diabetogenic cells in NOD mice. Diabetes 2008;57: 387-394
38. Lin GJ, Huang SH, Chen YW, et al. Transgenic expression of murine chemokine decoy receptor D6 by islets reveals the role of inflammatory CC chemokines in the development of autoimmune diabetes in NOD mice. Diabetologia 2011;54: 1777-1787
39. Yamada Y, Okubo Y, Shimada A, et al. Acceleration of diabetes development in CXC chemokine receptor 3 (CXCR3)-deficient NOD mice. Diabetologia 2012;55: 2238-2245
40. Solomon M, Balasa B, Sarvetnick N. CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse. Autoimmunity 2010;43: 156-163
41. Lukic ML, Mensah-Brown E, Wei X, Shahin A, Liew FY. Lack of the mediators of innate immunity attenuate the development of autoimmune diabetes in mice. J Autoimmun 2003;21: 239-246
42. Gerling IC, Friedman H, Greiner DL, Shultz LD, Leiter EH. Multiple lowdose streptozocin-induced diabetes in NOD-scid/scid mice in the absence of functional lymphocytes. Diabetes 1994;43: 433-440
43. Moepps B, Nuesseler E, Braun M, Gierschik P. A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Mol Immunol 2006;43: 897-914
44. Fan X, Patera AC, Pong-Kennedy A, et al. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem 2007;282: 11658-11666
45. Fu W, Zhang Y, Zhang J, Chen WF. Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1. Cytokine 2005;31: 9-17
46. Garabatos N, Alvarez R, Carrillo J, et al. In vivo detection of peripherinspecific autoreactive B cells during type 1 diabetes pathogenesis. J Immunol 2014;192: 3080-3090
47. Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One 2014;9: E83575
48. Hu C, Du W, Zhang X, Wong FS, Wen L. The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice. J Immunol 2012; 188: 294-301
49. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: Positioning cells for host defense and immunity. Annu Rev Immunol 2014;32: 659-702
50. Greenbaum CJ, Anderson AM, Dolan LM, et al.; SEARCH Study Group. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009;32: 1839-1844
51. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361: 2143-2152
52. Herold KC, Gitelman SE, Ehlers MR, et al.; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62: 3766-3774
53. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359: 1909-1920
54. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: Pilot randomized, placebo-controlled, doubleblind study. Diabetes Care 2009;32: 1244-1249